Related Experiment Videos
[First somatic human gene therapy in the USA approved]
Diskussionsforum Medizinische Ethik
|September 1, 1990
Insights
Gene therapy is now approved for infants with adenosine deaminase (ADA) deficiency, a severe combined immunodeficiency. This marks a significant milestone as the first federally approved somatic gene therapy.
Area of Science:
- Immunology
- Genetics
- Biotechnology
Context:
- Severe combined immunodeficiency (SCID) is a group of rare genetic disorders.
- Adenosine deaminase (ADA) deficiency is a specific cause of SCID, leading to a severely compromised immune system.
- Gene therapy offers a potential treatment for genetic disorders by modifying a patient's genes.
Purpose:
- To outline the approval of a clinical protocol for gene therapy in infants with ADA-SCID.
- To highlight the regulatory review process and its outcome.
Summary:
- A clinical protocol for treating infants with ADA-SCID using gene therapy has received approval.
- The Human Gene Therapy Subcommittee and RAC at NIH completed their review on July 30th.
- This approval signifies the commencement of the first federally sanctioned somatic gene therapy trial.
Impact:
- Paves the way for innovative treatments for primary immunodeficiencies.
- Represents a critical advancement in the field of human gene therapy.
- Offers hope for infants diagnosed with ADA-SCID and potentially other genetic disorders.
Abstract:
The clinical protocol to treat infants with severe combined immuno deficiency due to adenosine deaminase (ADA) deficiency by means of gene thereapy has been approved recently. The Human Gene Therapy Subcommittee and the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) concluded the review on July 30th and opened the door for the first federally approved somatic Human Gene Therapy.